ASRS 40TH ANNUAL
SCIENTIFIC MEETING

July 13 – 16, 2022
New York, NY
WEDNESDAY, JULY 13

3:30-5:35 PM Retina Case Conference
Moderator: Dean Elliott, MD
Vishal Agrawal, MD, FRCS, FACS, FASRS
Nikhil Batra, MD
Kevin Blinder, MD, FASRS
Daniel Brill, MD
Avni Finn, MD, MBA
Ronald Gentile, MD
R. Rishi Gupta, MD
Srinivas Joshi, MD, FASRS
M. Ali Khan, MD, FACS, FASRS
Jaclyn Kovach, MD
Brian Lee, MD
Jong Park, MD
Prethy Rao, MD, MPH
Ahmad Rehmani, DO
Lincoln Shaw, MD
Bradley Smith, MD, FASRS
Manju Subramanian, MD
Eduardo Uchiyama, MD, FACS, FASRS
Lejla Vajzovic, MD, FASRS
Nita Vallikodath, MD, MS
Taku Wakabayashi, MD
Jay Wang, MD
Christina Weng, MD, MBA, FASRS
David Xu, MD
Yoshihiro Yonekawa, MD, FASRS

6:30-10:00 PM Opening Reception at Cipriani 42nd Street*

THURSDAY, JULY 14

7:30-8:30 AM Continental Breakfast

8:00-8:05 AM Opening Comments, Jonathan Prenner, MD, FASRS

8:05-9:00 AM Wet AMD 1 Symposium
Moderators: Judy Kim, MD, FASRS and Sophie Bakri, MD

8:05 AM Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity, Justis Ehlers, MD, FASRS

8:09 AM Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials, Arshad Khanani, MD, MA, FASRS

8:15 AM UBX1325, A Novel Senolytic Therapy for Treatment-Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study, Raj Maturi, MD

8:19 AM Discussion

8:31 AM Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring, Michael Elman, MD

8:35 AM Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis, Dan Gong, MD

8:41 AM Subretinal Pneumatic Displacement Without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes, Marwan Abdulaal, MD
### 8:45 AM
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study, **Carl Danzig, MD**

### 8:49 AM
Discussion

### 9:00-9:30 AM
**Dry AMD 1 Symposium**

**Moderators:** Jeffrey Heier, MD and Caroline Baumal, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy, <strong>Jeffrey Heier, MD</strong></td>
<td></td>
</tr>
<tr>
<td>9:06 AM</td>
<td>Assessment of Geographic Atrophy Lesion Progression in the Phase 3 OAKS and DERBY Trials, <strong>Roger Goldberg, MD, MBA</strong></td>
<td></td>
</tr>
<tr>
<td>9:10 AM</td>
<td>Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes, <strong>Johanna Seddon, MD, ScM</strong></td>
<td></td>
</tr>
<tr>
<td>9:16 AM</td>
<td>Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials, <strong>Caroline Baumal, MD</strong></td>
<td></td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 9:30-10:10 AM
**Break**

### 10:10-10:50 AM
**Diabetic Retinopathy 1 Symposium**

**Moderators:** Jennifer Lim, MD, FARVO, FASRS and Joel Pearlman, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 AM</td>
<td>Afiblercept Monotherapy vs Initial Bevacizumab Followed by Afiblercept if Needed for Treatment of Center-Involved Diabetic Macular Edema, <strong>Chirag Jhaveri, MD, FASRS</strong></td>
<td></td>
</tr>
<tr>
<td>10:16 AM</td>
<td>Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials, <strong>David Eichenbaum, MD, FASRS</strong></td>
<td></td>
</tr>
<tr>
<td>10:22 AM</td>
<td>Randomized Phase 1 Trials of RZ402, a Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema, <strong>Robert Bhistikul, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>10:26 AM</td>
<td>Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema, <strong>Karl Csaky, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>10:32 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:42 AM</td>
<td>Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy, <strong>Michael Allingham, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>10:46 AM</td>
<td>Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post Fac, <strong>Christopher Riemann, MD</strong></td>
<td></td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Investigating the Utility of Near-Infrared Reflectance Imaging for Diabetic Retinopathy Screening, <strong>Mina Naguib, MD</strong></td>
<td></td>
</tr>
<tr>
<td>10:54 AM</td>
<td>Progressive Quantitative Outer Retinal Optical Coherence Tomography Abnormalities in Early Diabetic Retinopathy Compared with Controls, <strong>Jennifer Lim, MD, FARVO, FASRS</strong></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 11:10 AM-12:05 PM
**Surgery Symposium 1**

**Moderators:** Maria Berrocal, MD and Gaurav Shah, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 AM</td>
<td>Visual Outcomes and Complications of Combined vs Sequential Cataract Surgery and Pars Plana Vitrectomy: Multicenter Database Study, <strong>Ahmed Sallam, MD, PhD, FRCOPat</strong></td>
<td></td>
</tr>
</tbody>
</table>
11:16 AM Retinal Displacement After Scleral Buckle vs Combined Scleral Buckle and Vitrectomy for the Management of Rhegmatogenous Retinal Detachment: ALIGN SB vs PPV-SB, Aditya Bansal, MD

11:20 AM Randomized Controlled Trial of Perioperative Intravenous Dexmethasone on Postoperative Analgesia in Scleral Buckle Surgery, Jonathan Prenner, MD, FASRS

11:26 AM Surgical Outcomes of Combined Pars Plana Vitrectomy and Scleral Fixation of Intraocular Lenses: Comparison of Gore-Tex Suture vs Intrascleral Haptic Fixation, David Xu, MD

11:32 AM Discussion

11:41 AM Study of Simulated Vitreoretinal Performance After Multimodal Pharmacological and Behavioral Exposures Among Surgeons With Varying Levels of Surgical Experience, Mauricio Maia, MD, PhD

11:47 AM Retinal Massager: New Multifunctional Tool for Vitrectomy, Manish Nagpal, MD, FRCS (UK), FASRS

11:51 AM Surgical Outcomes of Scleral Buckling for Rhegmatogenous Retinal Detachment Using the NGENUITY 3-Dimensional Visualization System With a Guarded Light Pipe, John Miller, MD

11:57 AM Discussion

12:05-1:20 PM CONCURRENT SESSIONS

12:05-1:20 PM General Lunch

12:05-1:20 PM Fellowship Directors Lunch

12:05-1:20 PM Instructional Course: ASRS Research and Therapeutics (ReST) Committee Symposium—Clinical Trials “Unplugged”—Real, Practical Questions and Answers

Course Director: Peter Kaiser, MD, FASRS
Faculty: Ferhina S. Ali, MD, MPH; Fernando Arevalo, MD, PhD, FACS, FASRS; Caroline Bauml, MD; Netan Choudhry, MD, FACS(C), FASRS; Roger A. Goldberg, MD, MBA; Henry A. Leder, MD; Eric W. Schneider, MD; Lejla Vajzovic, MD, FASRS

12:05-1:20 PM Instructional Course: Vitreoretinal Surgical Rounds

Course Director: Paul Hahn, MD, PhD, FASRS
Faculty: Maria Berrocal, MD; Donald D’Amico, MD; Sharon Fekrat, MD, FACS, FASRS; John Kitchens, MD; Gregory Lee, MD; Yannek Leiderman, MD, PhD; Lisa Olmos de Koo, MD, MBA; Flavio Rezende, MD, PhD; Gaurav Shah, MD

1:20-2:25 PM Surgery Symposium 2

Moderators: Eric Nudleman, MD, PhD and Aleksandra Rachitskaya, MD, FASRS

1:20 PM Multilayered Inverted Internal Limiting Membrane Flap Technique vs Standard Internal Limiting Membrane Peeling for Large Macular Holes: Comparative Study

Vishal Agrawal, MD, FRCs,FACS,FASRS

1:26 PM Pars Plana Vitrectomy for Symptomatic Vitreous Opacities: Large Multicenter Case Series

Samuel Houston, MD, FASRS

1:30 PM Epiretinal Human Amniotic Membrane Grafting for Complex Surgical Macular Pathologies

Tongalp Tezel, MD

1:36 PM Scleral Imbrication and Fovea-Sparing ILM Peel as a Treatment for Myopic Foveoschisis, Fong May Chew, FRCOphth, MBBS, BSc
1:42 PM  Discussion
1:50 PM  Endophthalmitis After Pars Plana Vitrectomy Without Postoperative Topical Antibiotics, Tahsin Khundkar, MD
1:54 PM  Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials, Glenn Yiu, MD, PhD
2:00 PM  Vitreoretinal Biopsy Techniques and the Role of Retinal Biopsy in Vitreoretinal Lymphoma: Single-Institution Experience, Sunil Srivastava, MD
2:06 PM  State of Pediatric Retinal Detachment Surgery in the United States: An Aggregated Electronic Health Record Analysis of 2200 Children, Yoshihiro Yonekawa, MD, FASRS
2:12 PM  Cutter-Based vs Forceps-Based Membrane Peeling for Removal of Epimacular Membranes Scott Walter, MD, MSc
2:16 PM  Discussion

2:25-3:00 PM  Imaging, Digital, Angiography Symposium
Moderators: Szilard Kiss, MD and Fabio Patelli, MD
2:25 PM  Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography: Observational Cohort Study, Young Hee Yoon, MD, PhD
2:31 PM  Level of Diabetic Retinopathy Severity Correlates to Degree of Quadrant Asymmetry in Both Single and Averaged Imaged OCTA Metrics, Jesse Jung, MD, FASRS
2:35 PM  Retinal Displacement On Fundus Autofluorescence Imaging: Only The Tip Of the Iceberg, Koby Brosh Heshin, MD, MHA
2:39 PM  Discussion
2:46 PM  Infrared Video for the Demonstration and Quantification of Macula-Involving Symptomatic Vitreous Opacities, Shawn Kavoussi, MD
2:50 PM  Regression Patterns of Central Serous Chorioretinopathy Using En Face Optical Coherence Tomography, Supriya Arora, MS
2:54 PM  Discussion

3:00-3:35 PM  Break

3:35-3:40 PM  ASRS Grassroots Advocacy: Making a Difference for your Patients and your Profession, Reginald Sanders, MD

3:40-4:10 PM  Disruptive Transformative Technology and Trends in the Retinal Sphere
Moderator: Reginald Sanders, MD
Panelists: David Eichenbaum, MD, FASRS, Jonathan Feistmann, MD and Jawad Qureshi, MD, MBA

4:10-5:00 PM  Inflammatory & Infectious Diseases Symposium
Moderators: Sunil Srivastava, MD and Dimosthenis Mantopoulos, MD, PhD
4:10 PM  Biomarkers in the Vitreous Humor Correlate With Alzheimer’s Disease and Chronic Traumatic Encephalopathy in Postmortem Eyes and Brain, Manju Subramanian, MD
4:16 PM  Association of OCT Choroidal Thickness Maps and Automated Fixed-Depth Intensity Maps With Disease Activity in Birdshot Chorioretinopathy, Keirnan Willett, MD
4:20 PM  Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis, Christopher Henry, MD
4:24 PM Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Uveitis: Integrated Analysis of 2 Clinical Trials, Steven Yeh, MD

4:30 PM Discussion

4:37 PM Ultra-Widefield Fluorescein Angiography and OCT Findings in Children and Young Adults With Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy, Arjun Sood, MD

4:41 PM Heterogeneous Presentations of De Novo and Recurrent Uveitis After COVID-19 Vaccination: Multicenter Report, Sruthi Arepalli, MD

4:47 PM Ocular Involvement in Candidemia Diagnosed by T2 vs Blood Culture With Recommendations on Screening for Endogenous Candida Endophthalmitis, John Mason, MD

4:53 PM Discussion

5:00-5:55 PM Surgery Symposium 3
Moderators: Paul Hahn, MD, PhD, FASRS and Dean Elliott, MD

5:00 PM Opportunity Cost of Vitreoretinal Surgeries Ella Leung, MD

5:04 PM Economic Impact of Retina Procedure Volume Changes Due to the COVID-19 Pandemic: Analysis of 2020 Medicare Data, Shriji Patel, MD, MBA

5:08 PM Feature Tracking and Image Segmentation in Real Time via Deep Learning in Vitreoretinal Surgery: Framework for AI-Mediated Surgical Guidance, Yannek Leiderman, MD, PhD

5:14 PM Novel Technique for Capsular Tension Ring Exchange With Concomitant Intraocular Lens Exchange, Howard Fine, MD, MHSc

5:18 PM Discussion

5:26 PM Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry, Sunir Garg, MD, FACS, FASRS

5:32 PM Timing of Delayed Retinal Pathology in Patients Presenting With Acute Posterior Vitreous Detachment in the IRIS Registry, Gautam Vangipuram, MD


5:40 PM Two-Year Evaluation of Subretinal Fluid Drainage Techniques in Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment (ELLIPSOID-2 Study), Bryon McKay, MD, PhD, FRCSC

5:46 PM Discussion

6:00-6:45 PM Diversity, Equity and Inclusion Committee All-Welcome Reception: A Celebration of our Diversity

6:00-7:00 PM Scientific Poster Q&A and Exhibit Hall Reception

7:00-7:30 PM Fellows-in-Training & Resident Reception
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-8:30 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00-9:10 AM</td>
<td>Wet AMD 2 Symposium</td>
<td>Moderators: Anat Loewenstein, MD and Charles Wykoff, MD, PhD, FASRS</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database</td>
<td>Anita Barikian, MD</td>
</tr>
<tr>
<td>8:04 AM</td>
<td>AI-Based Spatiotemporal Observations of Retinal Fluid Dynamics Using the Notal Vision Home OCT</td>
<td>Anat Loewenstein, MD</td>
</tr>
<tr>
<td>8:10 AM</td>
<td>Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the PDS</td>
<td>Veeral Sheth, MD, MBA, FASRS, FACS</td>
</tr>
<tr>
<td>8:16 AM</td>
<td>ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update</td>
<td>Dante Pieramici, MD</td>
</tr>
<tr>
<td>8:22 AM</td>
<td>Phase IIib TALON Study of Brolucizumab Versus Afiblercept in a Matched Treat-and-Extend Regimen to Treat Neovascular AMD: 32-week Primary Outcomes</td>
<td>Carl Regillo, MD</td>
</tr>
<tr>
<td>8:28 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:37 AM</td>
<td>End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD</td>
<td>Aleksandra Rachitskaya, MD, FASRS</td>
</tr>
<tr>
<td>8:43 AM</td>
<td>Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand (TOWER) Study Report No. 2: The Fluid Analysis</td>
<td>Yodpong Chantarasorn, MD</td>
</tr>
<tr>
<td>8:47 AM</td>
<td>Long-Term Use of Antivascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration</td>
<td>Tedi Begaj, MD</td>
</tr>
<tr>
<td>8:53 AM</td>
<td>Prophylactic Intraocular Pressure-Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis</td>
<td>Parnian Arjmand, MD, MSc, FRCSC</td>
</tr>
<tr>
<td>8:57 AM</td>
<td>12-Month Results of EYP-1901 Vorolanib in a Biodegradable Duraret Insert for nAMD: The DAVIO Trial</td>
<td>Rishi Singh, MD</td>
</tr>
<tr>
<td>9:03 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:10-10:05 AM</td>
<td>Dry AMD 2 Symposium</td>
<td>Moderators: Marco Zarbin, MD, PhD and Johanna Seddon, MD, ScM</td>
</tr>
<tr>
<td>9:10 AM</td>
<td>Inhibition of Clq Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy</td>
<td>Patrick Williams, MD</td>
</tr>
<tr>
<td>9:16 AM</td>
<td>Platform for Screening Compounds for Treatment of AMD Using iPSC-derived Human RPE: Examples Using Elamipretide and SBT-272</td>
<td>Lucian Del Priore, MD, PhD</td>
</tr>
<tr>
<td>9:22 AM</td>
<td>Screening Mitochondrial-Targeted Drugs in iPSC-RPE from Patients With Dry Age-Related Macular Degeneration</td>
<td>Sandra Montezuma, MD, FASRS</td>
</tr>
<tr>
<td>9:26 AM</td>
<td>Association of Metformin and Other Antidiabetic Medication Use with Risk of Age-Related Macular Degeneration</td>
<td>Dimitra Skondra, MD, PhD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
9:42 AM Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years, Ehsan Rahimy, MD
9:48 AM Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis, Durga Borkar, MD
9:54 AM Discussion

10:05-10:35 AM JVRD “Best of the First 6 Years” Panel
Moderator: Donald J. D’Amico, MD
Speakers:
John Hinkle, MD
Matthew Sapp, MD
Steven Yeh, MD
Timothy Murray, MD, MBA, FASRS

10:35-11:15 AM Break

11:15 AM-12:40 PM Awards Ceremony
Moderators: Jonathan Prenner, MD, FASRS and Philip Ferrone, MD, FASRS
11:15 AM 2022 Pyron Award Introduction, Jonathan Prenner, MD, FASRS
11:17 AM 2022 Pyron Award, Targeting Pathologic Signaling to Restore Homeostasis in Retinal Diseases, Mary Elizabeth Hartnett, MD, FACS, FARVO, FASRS
11:30 AM 2021 Founders Award Introduction, Carl Awh, MD, FASRS
11:32 AM 2021 Founders Award, Human Amniotic Membrane in Vitreoretinal Surgery: Evolution of a Revolution, Stanislao Rizzo, MD
11:45 AM 2022 Founders Award Introduction, Philip Ferrone, MD, FASRS
11:47 AM 2022 Founders Award, A Life of Diabetic Vitrectomy: What a Disease Has Taught Me, Maria Berrocal, MD
12:00 PM Early Career Section (ECS) Crystal Apple Awards Presentation to Sharon Fekrat, MD, FACS, FASRS
12:05 PM ASRS Presidents’ Retina Young Investigators Award Introduction, Carl Awh, MD, FASRS
12:07 PM ASRS Presidents’ Retina Young Investigators Award, My Road From Intraoperative OCT to Imaging Biomarker Discovery: A Journey Towards Precision Medicine, Justis Ehlers, MD, FASRS
12:15 PM Packo Award Introduction, Philip Ferrone, MD, FASRS
12:20 PM Packo Award Presentation to Suber Huang, MD, MBA, FASRS
12:28 PM Retina Image Bank Award presented by Suber Huang, MD, MBA, FASRS
12:30 PM Retina Hall of Fame Award presented by Tarek Hassan, MD, FASRS

12:40-1:55 PM CONCURRENT SESSIONS

General Lunch

Early Career Section Lunch
Instructional Course: OCT Angiography in Clinical Practice
Course Director: Caroline Baumal, MD
Faculty: Talia Kaden, MD; Amir Kashani, MD, PhD; Aleksandra Rachitskaya, MD, FASRS; and Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO

Instructional Course: How Imaging Helped Me Nail the Diagnosis—Cases From The Experts
Course Director: Yasha Modi, MD
Faculty: Vaidehi Dedania, MD; Sunil Srivastava, MD; Rishi Singh, MD; Leila Vajzovic, MD; Priya Vakharia, MD, FASRS

1:55-2:05 PM Business Meeting (members only)

2:05-2:10 PM PAT Survey, Paul Hahn, MD, PhD, FASRS

2:10-2:15 PM Global Trends, Sunir Garg, MD, FACS, FASRS

2:15-3:10 PM Diabetic Retinopathy 2 Symposium
Moderators: Carl Regillo, MD and Young Hee Yoon, MD, PhD

2:15 PM Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of DR Worsening Over Time: Results of DRCR Retina Network Protocol AA, Dennis Marcus, MD

2:19 PM New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus, Bobeck Modjtahedi, MD

2:23 PM Long-Term Real-World Treatment Patterns Among Patients With Diabetic Macular Edema Initiating Anti-VEGF: 6-year Follow-up Using the IRIS Registry, Theodore Leng, MD, MS, FASRS

2:31 PM Discussion

2:41 PM Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study, Charles Wykoff, MD, PhD, FASRS

2:47 PM Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema, John Kitchens, MD

2:53 PM Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time, Paolo Antonio Silva, MD

2:57 PM Treat-and-Extend vs Alternate Dosing Strategies With Anti-VEGF Agents to Treat Center-Involving Diabetic Macular Edema: Meta-Analysis of Trials, Varun Chaudhary, MD

3:01 PM Discussion

3:10-4:05 PM Surgery Symposium 4
Moderators: Carl Awh, MD, FASRS and Stanislao Rizzo, MD

3:10 PM Fibrin Glue-Assisted Retinopexy for Rhegmatogenous Retinal Detachments: GUARD Study; Long-Term Outcomes of a New Surgical Technique With No Silicone Oil or Gas Tamponade, Mudit Tyagi, MS

Friday, July 15

ASRS 2022 ANNUAL MEETING | 8
3:16 PM Intravitreal Methotrexate Reduces Reoperation Rate and Improves Vision After Vitrectomy for Retinal Detachment, Trauma, and Proliferative Diabetic Retinopathy, Alan Franklin, MD, PhD

3:22 PM Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study, Sally Ong, MD

3:28 PM Long-Term Visual Outcomes of Fovea-Splitting Rhegmatogenous Retinal Detachments, Jeremy Wolfe, MD, MS

3:32 PM Discussion

3:42 PM Clinical Outcomes After Repair of Primary Acute Rhegmatogenous Retinal Detachment With Scleral Buckle, Sushant Wagley, MD

3:48 PM Outcomes of Pars Plana Vitrectomy Alone vs Combined Scleral Buckling Plus Pars Plana Vitrectomy for Primary Retinal Detachment, Luis Haddock, MD

3:52 PM Clinical Outcomes of Rhegmatogenous Retinal Detachment Repair in Pseudophakic Eyes With Multifocal Intraocular Lenses, Abtin Shahlaee, MD

3:58 PM Impact of Foveal Status and Timing of Surgery on Visual Outcome in Rhegmatogenous Retinal Detachment, Zeeshan Haq, MD

4:05-4:45 PM Break

4:45-5:30 PM Ocular Oncology Symposium
Moderators: Basil Williams, MD and Amy Schefler, MD, FACS, FASRS

4:45 PM Early Targeted Treatment for Uveal Melanoma Markedly Reduces Mortality: Evaluation of a Large Cohort of Class 2 GEP-Treated Small Ocular Melanoma Patients, Timothy Murray, MD, MBA, FASRS

4:51 PM Likelihood of Germline Mutation With Solitary Unilateral Retinoblastoma Based on Patient Age at Presentation: Real-World Analysis of 482 Consecutive Patients, Carol Shields, MD

4:57 PM Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2), Prithvi Mruthyunjaya, MD, MHS

5:03 PM Discussion

5:09 PM Clinical Features in Advanced Retinoblastoma: High-Risk Pathology and Metastatic Death, Paul Finger, MD, FACS

5:15 PM Application of a Novel Semi-Supervised Machine Learning Approach to Identify Choroidal Tumors From Fundus Photographs, Armin Afshar, MD, MBA, MAS

5:19 PM Gene Expression Profile and Local Tumor Recurrence of Irradiated Uveal Melanomas, Basil Williams, MD

5:23 PM Discussion

5:30-6:00 PM Surgery Symposium 5
Moderators: Tarek Hassan, MD, FASRS and Lisa Olmos de Koos, MD, MBA

5:30 PM Factors Associated With COVID-19 Vaccine Hesitancy and Clinical Trends in the Presentation of Primary Rhegmatogenous Retinal Detachments, Peter Tang, MD, PhD
5:34 PM Giant Retinal Detachment: Etiologies, Clinical Presentation, and Treatment Outcomes, Vishal Raval, MBBS, DNB, FMRF, FASRS
5:38 PM Fellow-Eye Retinal Detachment Risk as Stratified by Hyaloid Status on Optical Coherence Tomography, Josh Wallsh, MD
5:44 PM Multimodal Imaging Predictors of Functional Outcomes Following Rhegmatogenous Retinal Detachment Repair, Wei Wei Lee, MD
5:50 PM Discussion

6:00-6:20 PM Technology Symposium
Moderators: Scott Walter, MD, MSc and Yannek Leiderman, MD, PhD
6:00 PM Evaluation of a Robotically Aligned Optical Coherence Tomography System and Artificial Intelligence in Patients from the Emergency Department, Nita Valikodath, MD, MS
6:04 PM Real-Time Diagnosis of Diabetic Retinopathy by a Handheld Retinal Camera, Artificial Intelligence and Simultaneous Specialist Confirmation: Closing the Gap, Gustavo Melo, MD, PhD, FASRS
6:08 PM Smartphone-Based Home Vision Monitoring: Enablers and Barriers to Deployment in Clinical Practice Settings, Edward Korot, MD
6:12 PM Discussion

6:20-7:50 PM WinR Case Conference
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-8:30 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00-9:35 AM</td>
<td>Retinal Vascular Disease Symposium</td>
<td>Dante Pieramici, MD, FACS, FASRS</td>
</tr>
<tr>
<td></td>
<td>Subclinical Retinal Ischemia in Individuals With Atrial Fibrillation</td>
<td>Mathieu Bakhoum, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Point of Care Diagnosis of CRAO With OCT at the Stroke Center: Lessons</td>
<td>Gareth Lema, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Effects of Time Since Diagnosis to Intravitreal Afibercept Injection</td>
<td>Dilsher Dhoot, MD</td>
</tr>
<tr>
<td></td>
<td>Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Dexamethazone vs Anti-VEGF Therapy</td>
<td>John Huang, MD</td>
</tr>
<tr>
<td>8:20 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Longitudinal Macular Thickness and Microvascular Changes in Children</td>
<td>Adrienne Scott, MD, FASRS</td>
</tr>
<tr>
<td></td>
<td>With Sickle Cell Disease</td>
<td></td>
</tr>
<tr>
<td>8:36 AM</td>
<td>Spatial Correlation Between Retinal Ischemia and Reactive Choroidal</td>
<td>Junyeop Lee, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Changes in Retinal Vein Occlusion</td>
<td></td>
</tr>
<tr>
<td>8:40 AM</td>
<td>Predicting Outcomes and Treatment Frequency After Monthly Afibercept</td>
<td>Yasha Modi, MD</td>
</tr>
<tr>
<td></td>
<td>for Macular Edema Secondary to Central Retinal Vein Occlusion: A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Machine-Learning Model Approach</td>
<td></td>
</tr>
<tr>
<td>8:46 AM</td>
<td>Prospective Randomized Trial of Treat-and-Extend Intravitreal Afibercept for Radiation Retinopathy: One-Year Outcomes</td>
<td>Amy Scheffler, MD, FACS, FASRS</td>
</tr>
<tr>
<td>8:52 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:01 AM</td>
<td>Characterization of Vascular Abnormalities in X-Linked Retinoschisis</td>
<td>Audina Berrocal, MD, FASRS</td>
</tr>
<tr>
<td></td>
<td>Using Widefield Digital Fluorescein Angiography</td>
<td></td>
</tr>
<tr>
<td>9:07 AM</td>
<td>National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity</td>
<td>Nimesh Patel, MD</td>
</tr>
<tr>
<td>9:11 AM</td>
<td>Long-Term Follow-up of Patients Treated With Laser for Retinopathy of Prematurity</td>
<td>Rita Ehrlich, MD</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Modeling Zone as a Proxy for Absolute Avascular Retina Area and</td>
<td>Darius Moshfeghi, MD, FASRS</td>
</tr>
<tr>
<td></td>
<td>Retinopathy of Prematurity Risk</td>
<td></td>
</tr>
<tr>
<td>9:21 AM</td>
<td>Rate of and Time for Complete Retinal Vascularization in Premature</td>
<td>Tso-Ting Lai, MD</td>
</tr>
<tr>
<td></td>
<td>Infants and Its Associated Factors</td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:35-10:15 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:15-11:20 AM</td>
<td>Dry AMD 3 Symposium</td>
<td>Neil Bressler, MD and Susan Bressler, MD, FASRS</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Assessment of the Inclusion of Racial/Ethnic Minorities in Retina</td>
<td>Vivienne Hau, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Clinical Trials</td>
<td></td>
</tr>
</tbody>
</table>
10:21 AM  Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis), Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO

10:27 AM  Preliminary Results from a Phase I/II Gene Therapy (FOCUS) of Subretinally Delivered GT005 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, Szilárd Kiss, MD

10:33 AM  Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa, Peter Kaiser, MD, FASRS

10:39 AM  Discussion

10:49 AM  Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy, Glenn Jaffe, MD

10:55 AM  Early Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study, David Lally, MD

10:59 AM  Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials, Eleonora Lad, MD, PhD

11:03 AM  Could We Save Lives With Retinal Imaging by Finding Undetected High-Risk Vascular Diseases?, R. Theodore Smith, MD PhD

11:09 AM  Discussion

11:20-11:50 AM  Surgery Panel
Moderator: J. Michael Jumper, MD, FASRS
Panelists: Gaetano Barile, MD; Kevin Blinder, MD, FASRS; John Kitchens, MD; Elizabeth Rossin, MD PhD and Gaurav Shah, MD

11:50 AM-1:05 PM  CONCURRENT SESSIONS

1:05-1:55 PM  Diabetic Retinopathy 3 Symposium
Moderators: Jennifer Sun, MD and Francesco Boscia, MD
1:05 PM Efficacy, Safety, and Immunogenicity of MYL-1701P Compared With Eylea in Participants With Diabetic Macular Edema: Multicenter Double-Masked Randomized Phase 3 Study, Susan Bressler, MD, FASRS

1:11 PM 0.19 mg Fluocinolone Acetonide Implant Leads to Superior Vision, Anatomical, and Treatment Burden Outcomes in Eyes With Better Baseline Visual Acuity (<20/40), Victor Gonzalez, MD

1:15 PM Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases, Matthew Starr, MD

1:21 PM Discussion

1:29 PM Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study), Rahul Khurana, MD, FASRS

1:35 PM HORNBILL: Phase 1/2a Study of Safety and Early Response of BI-X in Patients With Diabetic Retinopathy and Diabetic Macular Ischemia Treated With Panretinal Photocoagulation, Quan Nguyen, MD, MSc, FARVO, FASRS

1:39 PM Association Between DRSS Changes and Visual/Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA, Diana Do, MD, FASRS

1:43 PM Benefits and Value of Treatment for Diabetic Macular Edema, Paul Hahn, MD, PhD, FASRS

1:47 PM Discussion

1:55-2:55 PM Surgery Symposium 6

Moderators: Philip Ferrone, MD, FASRS and Vivienne Hau, MD, PhD

1:55 PM Pathophysiology and Implications of Outer Retinal Corrugations in Rhegmatogenous Retinal Detachment, Rajeev Muni, MD, MSc, FRCS(C), FASRS

2:01 PM Repair of Progressive Retinal Detachment Complicating Degenerative Retinoschisis: Surgical Management and Outcomes in Phakic Eyes, J. Fernando Arevalo, MD, PhD, FACS, FASRS

2:07 PM Proliferative Choroidopathy: Clinical Presentation and Surgical Pearls in Complex Retinal Detachment with Advanced Proliferative Vitreoretinopathy, Flavio Rezende, MD, PhD

2:13 PM Retinal Detachment Associated With Giant Retinal Tears in 2 Stages Using Short-Term Tamponade With Perfluorocarbon Liquid Against Single-Stage Vitrectomy, Naresh Kannan, MD, FNB(VR), MBA (HR), FASRS

2:17 PM Surgical Outcomes of Rhegmatogenous Retinal Detachment in Patients 30 Years of Age or Younger at 3-Month, 1-Year, and 5-Year Follow-ups, Samuel Minaker, MD, MSc

2:23 PM Discussion

2:33 PM Localization of the Internal Limiting Membrane Flap After Macular Hole Surgery, Homayoun Tabandeh, MD, FASRS

2:37 PM Transretinal Subretinal Fluid Injection Technique for Refractory or Chronic Large Macular Holes, Gregory Lee, MD

2:41 PM Nasal Crowding and Nasal Tilting of the Macula After Epiretinal Membrane Surgery, Kyu Hyung Park, MD

2:47 PM Discussion
2:55-3:35 PM  Break

3:35-4:15 PM  Surgery Symposium 7
Moderators: Timothy Murray, MD, MBA, FASRS and Audina Berrocal, MD, FASRS

3:35 PM  Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials,
David Boyer, MD

3:39 PM  Dropless Vitrectomy Surgery for Epiretinal Membranes: Efficacy and Safety Compared to Standard of Care,
K. Chalam, MD, PhD, MBA, FRCS(C), FASRS

3:45 PM  Tips and Tricks in the Management of Complications Associated With Autologous Retinal Transplants,
Ryan Shields, MD

3:51 PM  Macular Hole Surgery Results With Long-Acting Gas Tamponade and Internal Limiting Membrane Removal,
John Thompson, MD

3:57 PM  Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia,
Lejla Vajzovic, MD, FASRS

3:57 PM  Scleral-Fixated Carlevale IOL: The Ultimate Solution,
Stratos Gotzaridis, MBBS, MD

4:03 PM  Discussion

4:15-5:05 PM  Wet AMD 3 Symposium
Moderators: Arshad Khanani, MD, MA, FASRS and Elizabeth Rossin, MD, PhD

4:15 PM  Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study,
W. Lloyd Clark, MD, FASRS

4:21 PM  Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD,
Neil Bressler, MD

4:27 PM  Anti-VEGF Injection Prior Authorization Impacts on Retina Practices, Sabin Dang, MD

4:33 PM  Discussion

4:41 PM  Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept, Mark Barakat, MD

4:47 PM  Noninferiority of 1.7% Povidone-Iodine for Endophthalmitis Prophylaxis After Intravitreal Injections Compared With 5% Povidone-Iodine in an Office Setting, Kamal Kishore, MD, MBBS

4:51 PM  Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics, Murtaza Adam, MD

4:57 PM  Discussion

5:05-5:15 PM  Poster and Film Awards

6:30-10:30 PM  Gala Dinner at American Museum of Natural History
The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this Other activity (blended live and enduring material) for a maximum of 26.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the ACCME’s Standards for Commercial Support, ASRS required all individuals controlling the content of this CME activity to disclose all financial relationships with any ineligible companies. ASRS implemented mechanisms to mitigate those relevant financial relationships to prevent commercial bias. Please see the program booklet (our mobile meeting site) for disclosure information for all planners and teachers of this CME activity.